Telios Pharma, Inc. Report issue

For profit Phase 2
Founded: San Diego CA United States (2019)

Organization Overview

First Clinical Trial
2020
NCT04419623
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Telios Pharma, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

krt-232 (2 trials)

ruxolitinib (jakafi) (1 trial)

tl-895 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hematologic Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Primary Myelofibrosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3